LivaNova RECOVER depression trial enrollment to continue to 450 patients per DSMB advice

LivaNova PLC

Independent Statistical Analysis Committee advised enrollment continue from 425 to 450 unipolar patients.
Trial remains on track; interim analyses every 25 patients assess predictive probability of success.
If successful, results could support peer-reviewed article and CMS reimbursement reconsideration for VNS Therapy.
No efficacy or safety signal disclosed; trial continues per protocol.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.